540359 — Parmax Pharma Income Statement
0.000.00%
Last trade - 00:00- IN₹1.68bn
- IN₹1.74bn
- IN₹110.53m
Annual income statement for Parmax Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2023 March 31st | 2024 March 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IAS | IAS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 154 | 111 |
| Cost of Revenue | ||
| Gross Profit | 99.3 | 40 |
| Selling / General / Administrative Expenses | ||
| Depreciation and Amortization | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 150 | 161 |
| Operating Profit | 3.75 | -50.8 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | 0.461 | -56.6 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -1.04 | -57.8 |
| Net Income Before Extraordinary Items | ||
| Net Income | -1.04 | -57.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Dilution Adjustment | ||
| Diluted Net Income | -1.04 | -57.8 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.28 | -15.4 |
| Dividends per Share |